Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 36

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

503

HTML

4326

Figures (1-1)

132

Tables (1-5)

144

Sum=5105

Sep 28, 2008 (publication date) through Oct 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Sep 28, 2008; 14(36): 5584-5589
Published online Sep 28, 2008. doi: 10.3748/wjg.14.5584

Table 3 FC levels (μg/g, mean, 10-90th percentile) in patients with a relapse of IBD at inclusion, and after 4 and 8 wk of treatment

¹Friedmans Test for 3 variables.

Citation: Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14(36): 5584-5589
URL: https://www.wjgnet.com/1007-9327/full/v14/i36/5584.htm
DOI: https://dx.doi.org/10.3748/wjg.14.5584